Locations:
Search
Neoadjuvant immunotherapy improves outcomes
Poor response may be due to different tumor biology
Oral medication may have potential to preserve vision and shrink tumors prior to surgery or radiation
Study examines the relationship between outcomes and delay
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Durvalumab monotherapy appears safe and well-tolerated
Advertisement
Advertisement